China Pharma Holdings Past Earnings Performance
Past criteria checks 0/6
China Pharma Holdings has been growing earnings at an average annual rate of 35.7%, while the Pharmaceuticals industry saw earnings declining at 0.8% annually. Revenues have been declining at an average rate of 9.5% per year.
Key information
35.7%
Earnings growth rate
41.8%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | -9.5% |
Return on equity | -41.3% |
Net Margin | -43.9% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How China Pharma Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 7 | -3 | 2 | 0 |
30 Sep 23 | 8 | -3 | 2 | 0 |
30 Jun 23 | 8 | -3 | 2 | 0 |
31 Mar 23 | 8 | -3 | 3 | 0 |
31 Dec 22 | 8 | -4 | 3 | 0 |
30 Sep 22 | 8 | -4 | 3 | 0 |
30 Jun 22 | 8 | -4 | 3 | 0 |
31 Mar 22 | 9 | -4 | 3 | 0 |
31 Dec 21 | 10 | -3 | 3 | 0 |
30 Sep 21 | 10 | -4 | 3 | 1 |
30 Jun 21 | 10 | -4 | 4 | 1 |
31 Mar 21 | 11 | -3 | 4 | 1 |
31 Dec 20 | 11 | -3 | 4 | 0 |
30 Sep 20 | 11 | -20 | 5 | 0 |
30 Jun 20 | 11 | -20 | 5 | 0 |
31 Mar 20 | 10 | -21 | 4 | 0 |
31 Dec 19 | 11 | -21 | 5 | 0 |
30 Sep 19 | 11 | -10 | 4 | 0 |
30 Jun 19 | 11 | -11 | 5 | 0 |
31 Mar 19 | 12 | -11 | 6 | 0 |
31 Dec 18 | 12 | -11 | 6 | 0 |
30 Sep 18 | 13 | -17 | 7 | 0 |
30 Jun 18 | 14 | -17 | 6 | 0 |
31 Mar 18 | 14 | -19 | 7 | 0 |
31 Dec 17 | 13 | -19 | 7 | 0 |
30 Sep 17 | 15 | -9 | 7 | 0 |
30 Jun 17 | 15 | -8 | 7 | 0 |
31 Mar 17 | 15 | -9 | 7 | 0 |
31 Dec 16 | 16 | -9 | 7 | 0 |
30 Sep 16 | 15 | -12 | 11 | 1 |
30 Jun 16 | 16 | -7 | 8 | 1 |
31 Mar 16 | 18 | -9 | 10 | 1 |
31 Dec 15 | 20 | -15 | 16 | 1 |
30 Sep 15 | 19 | -31 | 28 | 1 |
30 Jun 15 | 20 | -41 | 35 | 1 |
31 Mar 15 | 21 | -45 | 40 | 3 |
31 Dec 14 | 22 | -40 | 36 | 3 |
30 Sep 14 | 27 | -28 | 23 | 3 |
30 Jun 14 | 30 | -24 | 23 | 3 |
31 Mar 14 | 32 | -20 | 20 | 2 |
31 Dec 13 | 33 | -20 | 16 | 2 |
30 Sep 13 | 36 | -11 | 14 | 2 |
30 Jun 13 | 40 | -7 | 11 | 1 |
Quality Earnings: CPHI is currently unprofitable.
Growing Profit Margin: CPHI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CPHI is unprofitable, but has reduced losses over the past 5 years at a rate of 35.7% per year.
Accelerating Growth: Unable to compare CPHI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CPHI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.7%).
Return on Equity
High ROE: CPHI has a negative Return on Equity (-41.3%), as it is currently unprofitable.